Diabetes Care Jul;32(7):1224-30, 2009
Rybelsus est contraindicado en pacientes con antecedentes personales o familiares de carcinoma medular de tiroides o sndrome de neoplasia endocrina mltiple tipo 2 (MEN 2)

Contact your healthcare provider if you experience: Severe or persistent cramps that do not respond to self-care measures or significantly impact your quality of life and daily activities Frequent cramping occurring multiple times daily or nightly, disrupting sleep and functioning Associated symptoms including muscle weakness, numbness, tingling, or changes in sensation, which may suggest neurological involvement Swelling, redness, or warmth in the affected leg, which could indicate deep vein thrombosis or other vascular complications Severe gastrointestinal symptoms with signs of dehydration such as decreased urination, dizziness, confusion, or rapid heartbeat Cramps that began after starting semaglutide and persist despite adequate hydration and nutritional measures Seek immediate medical attention (call 911) if you develop: Chest pain, shortness of breath, or severe abdominal pain Signs of severe dehydration including inability to keep down fluids, minimal urine output, or altered mental status Symptoms suggesting acute kidney injury, such as significantly decreased urination, swelling, or confusion Your healthcare provider can perform a comprehensive evaluation including physical examination, review of your medication regimen, and laboratory testing to assess electrolyte levels, kidney function, and other relevant parameters

doi: 10.3389/fendo.2021.626427 Received 09 November 2020 Accepted 06 April 2021 Published 28 April 2021 Volume 12 - 2021 Edited by Nienke Biermasz, Leiden University, Netherlands Reviewed by Luiz Augusto Casulari, University of Brasilia, Brazil